Document:

<PAGE>
                                                                   Exhibit 10.70

                        CONFIDENTIAL TREATMENT REQUESTED
                        --------------------------------

5

                                March 24, 2000

Amarin Corporation PLC
Gemini House
Bartholomew's Walk
Ely, Cambs
CB7 4EA, United Kingdom

Gentlemen:

Reference is made to the certain (i) License & Development Agreement, dated
January 15, 1993, between Schein Pharmaceutical, Inc. ("Schein") and Ethical
Holdings plc (formerly known as Ethical Holdings Limited; now known as Amarin
Corporation plc), as amended by that certain Amendment Agreement, dated
November 4, 1994 (the "* Agreement"), between Schein and Ethical Holdings,
plc; (ii) License & Development Agreement, dated March 31, 1994 (the "*
Agreement"), between Schein and Ethical Holdings plc; and (iii) License &
Development Agreement, dated November 30, 1993 (the "* Agreement"), between
Schein and Ethical Holdings plc. Ethical Holdings Limited, Ethical Holdings,
plc and Amarin Corporation plc are hereafter referred together as "Amarin."
The * Agreement, the * Agreement and * Agreement are hereafter referred to
collectively as the "Development Agreements". This letter of agreement (the
"Letter") will confirm our understanding and agreement regarding the
amendment and termination of the Development Agreements, in whole or part, as
follows:

1.   * AGREEMENT.

     (a) TERMINATION OF * AGREEMENT WITH RESPECT TO US DEVELOPMENT RIGHTS.
Subject to the terms and conditions contained herein, the term of the *
Agreement with respect to the license, development, manufacture, supply, sale
and distribution of * in the United States of America, its territories and
possessions (the "US Development Rights") shall terminate with immediate
effect from the date of this Letter, provided, however, that the rights and
obligations of the parties under Article XI.B of the * Agreement with respect
to the US Development rights shall survive for a period of seven (7) years
from the date hereof and under Articles XII and XIX of the * Development
Agreement shall survive termination of the term of the * Agreement with
respect to the US Development Rights.

----------
*    Material omitted pursuant to a request for confidential treatment. The
     omitted material has been filed separately with the Securities and Exchange
     Commission.

<PAGE>

     (b) AMENDMENT OF * AGREEMENT WITH RESPECT TO INTERNATIONAL DEVELOPMENT
RIGHTS. Amarin and Schein hereby acknowledge that the Development Programme
(as that term is defined in the * Agreement) for * in all territories outside
of the United States of America, its territories and possessions (the
"International Development Programme") has been completed and that all
obligations of the parties regarding the International Development Programme
have been fulfilled. All other rights and obligations of the parties concerning
the license and commercialization of * in all territories outside of the United
States of America, its territories and possessions shall continue.

     (c) In consideration of the agreements contained herein, Amarin agrees to
reimburse Schein (a) the sum of US * of past licensing fees paid by Schein to
Amarin with respect to the United States and (b), the sum of US * of past
licensing fees paid by Schein to Amarin and US * of development fees paid by
Schein with respect to countries in the Territory (as that term is defined in
the * Agreement) other than the United States, all in accordance with
Paragraph 4, below.

     2. TERMINATION OF * AGREEMENT. Subject to the terms and conditions
contained herein, the * Agreement shall terminate with immediate effect from
the date of this Letter; provided, however, that the rights and obligations
of the parties under Article XV.B of the * Agreement shall survive for a
period of seven (7) years from the date hereof and under Articles XVI and
XXIII of the * Agreement shall survive termination of the * Agreement.
In consideration of the agreements contained herein, Amarin agrees to
reimburse Schein the sum of US * of past licensing fees paid by Schein to
Amarin, in accordance with paragraph 4, below, and Schein agrees to transfer
to Amarin all of Schein's right, title and interest in and to the Licensee
Know-How (as that term is used in the * Agreement) and the IND related to the
Product (as that term is defined in the * Agreement), without recourse,
warranty or representation whatsoever.

     3. TERMINATION OF * AGREEMENT. Subject to the terms and conditions
contained herein, the * Agreement shall terminate with immediate effect from
the date of this Letter; provided, however, that the rights and obligations
of the parties under Article XII of the * Agreement shall survive for a
period of seven (7) years from the date hereof and under Articles XIII and XX
of the * Agreement shall survive termination of the * Agreement. In
consideration of the agreements contained herein, Amarin agrees to reimburse
Schein the sum of US * of past licensing fees paid by Schein to Amarin, in
accordance with paragraph 4, below, and Schein agrees to transfer to Amarin
all of Schein's right, title and interest in and to the Licensee Know-How (as
that term is used in the * Agreement) and the draft ANDA related to the
Product (as that term is defined in the * Agreement), without recourse,
warranty or representation whatsoever. Schein and Amarin shall negotiate in
good faith negotiate an agreement for Schein to package commercial quantities
of the Product in its facilities unless Amarin decides otherwise.

----------
*    Material omitted pursuant to a request for confidential treatment. The
     omitted material has been filed separately with the Securities and Exchange
     Commission.

                                       2

<PAGE>

     4. SCHEDULE OF PAYMENTS. The consideration payable to Schein pursuant to
paragraphs one (1), two (2) and (3) hereof, shall be made as follows:

          (a) CASH PAYMENTS. Cash totaling * United States dollars (US *) shall
be due and payable by Amarin to Schein on March 27, 2000;

Such payment shall be paid to Schein at its offices at 100 Campus Drive, Florham
Park, New Jersey 07932, U.S.A., or at such other location as Schein may direct
in writing. Late payments shall bear interest at a rate equal to the lower of
(i) LIBOR plus three (3%) per cent per annum or (ii) the maximum rate permitted
by law; and

          (b) The issue on the date of the completion ("Private Placement Date")
by Amarin of its current private placement of securities of not less than US
* (the "Private Placement") of * ordinary shares of Amarin (the "Shares"),
with such rights as are set out on Article VI of the Stock Purchase Agreement
to be executed in connection with the Private Placement in the form is
annexed hereto) between Amarin and the prospective purchasers, which Article
VI is deemed incorporated herein and made a part hereof as if Schein were a
Purchaser and Holder thereunder; none of such rights may be amended with
respect to Schein without Schein's prior written consent. The Shares shall be
convertible at Schein's option, within the period set out in Article VI(d) of
the Stock Purchase Agreement, into * American Depository Shares ("ADSs") of
Amarin in accordance with the registration rights set out in Article VI of
the Stock Purchase Agreement. Amarin agrees to use its best efforts at its
expense to file a registration statement in respect of such Shares within
ninety (90) days of issue. Schein shall pay all other costs related to the
issue of ADSs on registration. The provisions of Section 3.1 of Article III
of the Stock Purchase Agreement shall be deemed incorporated and made a part
hereof and such representations and warranties are deemed to be made by
Amarin to Schein in connection with the issue of the shares to Schein. The
Company also agrees (i) to provide Schein with copies of all notices it sends
to or receives from Purchasers under the Stock Purchase Agreement and (ii) to
pay Schein's proportionate share of reasonable attorneys' fees and
out-of-pocket expenses of counsel to the extent provided in Section 7.4 of
the Stock Purchase Agreement. The Company agrees that no material provision
of the Stock Purchase Agreements being entered into with the Purchasers in
connection with the Private Placement having an effect on the rights of
Schein granted under this clause, including without limitation, any
representations and warranties, shall be varied from the form annexed hereto,
without the prior written consent of Schein, not to be unreasonably withheld.

     5. Except for the obligations of Schein under paragraphs 1, 2, 3 and 4 of
this Letter, Amarin, for itself and each of its subsidiaries, parents,
affiliates, shareholders, officers, directors, partners, attorneys,
representatives, agents and employees of same, and the assigns and successors in
interest of any of the foregoing entities and individuals (hereinafter
individually and collectively referred to as the "Amarin Releasors"), does
hereby remise, release and forever discharge Schein and each of its
subsidiaries,

----------
*    Material omitted pursuant to a request for confidential treatment. The
     omitted material has been filed separately with the Securities and Exchange
     Commission.

                                       3

<PAGE>

affiliates, officers, directors, partners, attorneys, representative, agents and
employees of same, and the assigns and successors in interest of any of the
foregoing entities and individuals (hereinafter individually and collectively
referred to as the "Schein Releasees"), of and from any and all manner of
actions, causes of action, suits, debts, sums of money, contracts,
controversies, agreements, promises, damages, judgments, executions, claims,
liabilities, demands and obligations, in law or in equity, whether asserted now
or in the future, directly or indirectly by way of defense of set-off or
recoupment, or whether based on any theory of indemnification, contribution,
equitable apportionment or reimbursement of any kind, whether known or unknown,
foreseen or unforeseen, fixed or contingent, of any nature whatsoever, which
against the Schein Releasees, the Amarin Releasors ever had, now has or
hereafter can, shall, may or could have for, upon or by reason of any act,
omission, matter, cause or thing whatsoever from the beginning of time to the
date of this Release, arising out of or in connection with the * Agreement or
its termination or the US Development Rights under the * Agreement or the
termination of such rights.

     6. Except for the obligations of Amarin under paragraphs 1, 2, 3 and 4 of
this Letter, Schein, for itself and each of its subsidiaries, parents,
affiliates, shareholders, officers, directors, partners, attorneys,
representatives, agents and employees of same, and the assigns and successors in
interest of any of the foregoing entities and individuals (hereinafter
individually and collectively referred to as the "Schein Releasors"), does
hereby remise, release and forever discharge Amarin and each of its
subsidiaries, affiliates, officers, directors, partners, attorneys,
representatives, agents and employees of same, and the assigns and successors in
interest of any of the foregoing entities and individuals (hereinafter
individually and collectively referred to as the "Amarin Releasees"), of and
from any and all manner of actions, causes of action, suits, debts, sums of
money, contracts, controversies, agreements, promises, damages, judgments,
executions, claims, liabilities, demands and obligations, in law or in equity,
whether asserted now or in the future, directly or indirectly by way of defense
of set-off or recoupment, or whether based on any theory of indemnification,
contribution, equitable apportionment or reimbursement of any kind, whether
known or unknown, foreseen or unforeseen, fixed or contingent, of any nature
whatsoever, which against the Amarin Releasees, the Schein Releasors ever had,
now has or hereafter can, shall, may or could have for, upon or by reason of any
act, omission, matter, cause or thing whatsoever from the beginning of time to
the date of this Release, arising out of or in connection with the * Agreement
or * Agreement, or the termination thereof or the US Development Rights under
the * Agreement or the termination of such rights.

     7. Any disputes related to the terms of this Letter shall be in accordance
with the arbitration provisions of Development Agreements.

     8. This Letter may not be modified or amended except in a writing executed
by the parties hereto.

     9. Notwithstanding anything to the contrary contained herein, the
obligations and agreements of the parties hereunder are subject to and
conditioned upon the

----------
*    Material omitted pursuant to a request for confidential treatment. The
     omitted material has been filed separately with the Securities and Exchange
     Commission.

                                       4

<PAGE>

completion of the Private Placement in amount of not less than US *. In the
event such Private Placement is not completed by December31, 2000, this Letter
and the agreements contained herein shall become null and void AB INITIO and of
no further force or effect.

Please execute a copy of this Letter in the space provided below and return it
to the undersigned to indicate your agreement to the foregoing.

                                   Very truly yours,

                                   SCHEIN PHARMACEUTICAL, INC.

                                   By: /s/ Paul Kleutghen
                                       -----------------------------------
                                   Name: Paul Kleutghen
                                   Title: Senior Vice President, Strategic
                                          Development

ACCEPTED AND AGREED TO:

AMARIN CORPORATION PLC

By: /s/ Richard A.B. Stewart
    ------------------------------
Name: Richard A.B. Stewart
Title: President & CEO

----------
*    Material omitted pursuant to a request for confidential treatment. The
     omitted material has been filed separately with the Securities and Exchange
     Commission.

                                       5<PAGE>

                                                                  Exhibit 4.4

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION
STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR, AT THE
OPTION OF THE COMPANY, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED, OR UNLESS SOLD PURSUANT TO AN
EXEMPTION TO SUCH ACT.

                          COMMON STOCK PURCHASE WARRANT

                                JORE CORPORATION

         THIS CERTIFIES that, for value received, ___________________________,
or registered assigns, is entitled, upon the terms and subject to the
conditions hereinafter set forth, at any time or from time to time at or prior
to 11:59 p.m., Pacific time, on July 29, 2002 (the "EXPIRATION DATE"), to
acquire from Jore Corporation, a Montana corporation (the "COMPANY"),
__________________(____________) fully paid and nonassessable shares of common
stock, or its equivalent, however designated, of the Company (the "WARRANT
SHARES"), for $9.10 per share (the "EXERCISE PRICE"). The number of Warrant
Shares, type of security and Exercise Price are subject to adjustment as
provided herein.

1. EXERCISE OF WARRANT. This Warrant is exercisable by the registered holder
hereof, at any time and from time to time at or prior to the Expiration Date by
the surrender of this Warrant and delivery of a Notice of Exercise/Conversion,
the form of which is attached hereto as ANNEX A, duly executed to the principal
offices of the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered holder hereof), and upon
payment of the Exercise Price for the shares thereby purchased (by check payable
to the order of the Company or by wire transfer the account of the Company);
whereupon the Company shall issue to the holder of this Warrant the number of
Warrant Shares so purchased and shall deliver a stock certificate in proper form
representing such number of Warrant Shares.

2. CONVERSION OF WARRANT. The registered holder hereof shall have the right (but
not the obligation) to require the Company to convert this Warrant, in whole or
in part, at any time and from time to time at or prior to the Expiration Date,
by the surrender of this Warrant and delivery of a Notice of Exercise/Conversion
duly executed to the principal offices of the Company (or such other office or
agency of the Company as it may designate by notice in writing to the registered
holder hereof), into Warrant Shares as provided in this Section 2. Upon exercise
of this conversion right (and without payment by the holder of the Exercise
Price), the holder hereof shall be entitled to receive that number of Warrant
Shares determined in accordance with the following formula:

                      Warrant Shares Issuable to Holder = [ (A - B)x C ] +A

 where:

                  A =      the Fair Market Value (as defined below) of one
                           Warrant Share on the date of conversion of this
                           Warrant;

                  B =      the Exercise Price; and

                                       1
<PAGE>

                  C =      the number of Warrant Shares as to which this
                           Warrant is being converted.

         "Fair Market Value" of one Warrant Share shall mean:

         (a) if the conversion right is being exercised in connection with a
transaction specified in Section 9 hereof, the value of the consideration
(determined, in the case of non-cash consideration, in good faith by the Board
of Directors of the Company) to be received pursuant to such transaction by the
holder of one Warrant Share;

         (b) if the conversion right is being exercised after the occurrence of
an initial public offering of common stock of the Company, the average of the
high and low trading prices of a share of Common Stock as reported by the
principal securities exchange or market on which the common stock is listed for
trading for the three trading days prior to the surrender of this Warrant for
conversion in accordance with the terms hereof; or

         (c) in all other cases, the fair value as determined in good faith by
the Board of Directors of the Company.

         Upon conversion of this Warrant in accordance with this Section 2, the
registered holder hereof shall be entitled to receive a certificate for the
number of Warrant Shares determined in accordance herewith.

3. ISSUANCE OF SHARES; NO FRACTIONAL SHARES OR SCRIP. Certificates for shares
purchased upon exercise or issuable upon conversion hereof shall be delivered to
the holder by the Company's stock transfer agent at the Company's expense within
three business days after the date on which this Warrant shall have been
exercised or converted, as the case may be, in accordance with the terms hereof.
Each certificate so delivered shall be in such denominations as may be requested
by the holder hereof and shall be registered in the name of such holder or,
subject to applicable laws, any other name or names as shall be requested by
such holder; PROVIDED, HOWEVER, that in the event certificates for Warrant
Shares are to be issued in a name other than the name of the holder of this
Warrant, this Warrant when surrendered for exercise or conversion shall be
accompanied by an Assignment Form, the form of which is attached hereto as ANNEX
B, duly executed by the holder hereof. If, upon exercise or conversion of this
Warrant, fewer than all of the Warrant Shares evidenced by this Warrant are
purchased or issued prior to the Expiration Date, one or more new warrants of
like tenor to this Warrant will be issued for the remaining number of Warrant
Shares not purchased upon such exercise or issued upon such conversion. The
Company agrees that the shares so issued shall be deemed to be issued to such
holder as the record owner of such shares as of the close of business on the
date on which this Warrant shall have been surrendered for exercise or
conversion in accordance with the terms hereof. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise or conversion
of this Warrant. With respect to any fraction of a share otherwise issuable upon
the exercise or conversion of this Warrant, an amount equal to such fraction
multiplied by the then current price at which each share may be purchased
hereunder shall be paid in cash to the holder of this Warrant.

4. CHARGES, TAXES AND EXPENSES. Issuance of certificates for shares of Warrant
Shares upon the exercise or conversion of this Warrant shall be made without
charge to the holder hereof for any issue or transfer tax or other incidental
expense in respect of the issuance of such certificate, all of which taxes and
expenses shall be paid by the Company.

5. NO RIGHTS AS SHAREHOLDER. This Warrant does not entitle the holder hereof to
any voting rights or other rights as a shareholder of the Company prior to the
exercise or conversion hereof.

                                       2
<PAGE>

6. EXCHANGE AND REGISTRY OF WARRANT. This Warrant is exchangeable, upon the
surrender hereof by the registered holder at the principal above-mentioned
office or agency of the Company, for a new Warrant of like tenor and dated as of
such exchange. The Company shall maintain at its principal offices (or such
other office or agency of the Company as it may designate by notice in writing
to the registered holder hereof), a registry showing the name and address of the
registered holder of this Warrant. This Warrant may be surrendered for exchange,
transfer, exercise or conversion, in accordance with its terms, at such office
or agency of the Company, and the Company shall be entitled to rely in all
respects, prior to written notice to the contrary, upon such registry.

7. LOSS, THEFT, DESTRUCTION OR MUTILATION OF WARRANT. Upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant, and in case of loss, theft or
destruction of indemnity or security reasonably satisfactory to it, and upon
reimbursement to the Company of all reasonable expenses incidental thereto, and
upon surrender and cancellation of this Warrant, if mutilated, the Company will
make and deliver a new Warrant of like tenor and dated as of such cancellation,
in lieu of this Warrant.

8. SATURDAYS, SUNDAYS AND HOLIDAYS. If the last or appointed day for the taking
of any action or the expiration of any right required or granted herein shall be
a Saturday or a Sunday or shall be a legal holiday, then such action may be
taken or such right may be exercised on the next succeeding day not a legal
holiday.

9. MERGER, SALE OF ASSETS, ETC. If at any time the Company proposes to merge or
consolidate with or into any other corporation, effect any reorganization, or
sell or convey all or substantially all of its assets to any other entity, in a
transaction in which the shareholders of the Company immediately prior to
completion of the transaction will own immediately after completion of the
transaction less than a majority of the outstanding voting securities of the
entity (or its parent) succeeding to the business of the Company, then the
Company shall give the holder of this Warrant sixty (60) days' prior written
notice of the proposed effective date of such transaction, and if this Warrant
has not been exercised or converted by or on the effective date of such
transaction, it shall terminate.

10. SUBDIVISION, COMBINATION, RECLASSIFICATION, CONVERSION, ETC. If the Company
at any time shall, by subdivision, combination, reclassification of securities
or otherwise, change the Warrant Shares into the same or a different number of
securities of any class or classes, this Warrant shall thereafter entitle the
holder to acquire such number and kind of securities as would have been issuable
in respect of the Warrant Shares (or other securities which were subject to the
purchase rights under this Warrant immediately prior to such subdivision,
combination, reclassification or other change) as the result of such change if
this Warrant had been exercised in full for cash immediately prior to such
change. The Exercise Price hereunder shall be adjusted if and to the extent
necessary to reflect such change. If the Warrant Shares or other securities
issuable upon exercise or conversion hereof are subdivided or combined into a
greater or smaller number of shares of such security, the number of shares
issuable hereunder shall be proportionately increased or decreased, as the case
may be, and the Exercise Price shall be proportionately reduced or increased, as
the case may be, in both cases according to the ratio which the total number of
shares of such security to be outstanding immediately after such event bears to
the total number of shares of such security outstanding immediately prior to
such event. The Company shall give the holder prompt written notice of any
change in the type of securities issuable hereunder, any adjustment of the
Exercise Price for the securities issuable hereunder, and any increase or
decrease in the number of shares issuable hereunder.

                                       3
<PAGE>

11.      TRANSFERABILITY; COMPLIANCE WITH SECURITIES ACT

         (a) This Warrant shall inure to the benefit of the successors to and
assigns of the holder. Prior to the Expiration Date and subject to compliance
with applicable laws, this Warrant and all rights hereunder are transferable by
the holder hereof, in whole or in part, at the principal offices of the Company
(or such other office or agency of the Company as it may designate by notice in
writing to the registered holder hereof). Any such transfer shall be made in
person or by the holder's duly authorized attorney, upon surrender of this
Warrant together with a properly endorsed Assignment Form.

         (b) Each certificate representing the Warrant Shares or other
securities issued in respect of the Warrant upon any stock split, stock
dividend, recapitalization, merger, consolidation or similar event, shall bear a
legend substantially in the following form (in addition to any legend required
under applicable state securities laws):

         These securities have not been registered under the Securities Act of
         1933, as amended (the "Act"), or any state securities laws. They may
         not be sold, offered for sale, pledged, hypothecated or otherwise
         transferred n the absence of a registration statement in effect with
         respect to the securities under such act or, at the option of the
         company, an opinion of counsel reasonably satisfactory to the Company
         that such registration is not required, or unless sold pursuant to an
         exemption to such Act.

12. COOPERATION. The Company will not, by amendment of its charter documents or
through any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other action, avoid or
seek to avoid the observance or performance of any of the terms to be observed
or performed hereunder by the Company, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may be necessary or appropriate in order to protect
the rights of the holder of the Warrant against impairment.

13.      NOTICES OF RECORD DATE, ETC.  In the event of

                  (a) any taking by the Company of a record of the holders of
         any class of securities for the purpose of determining the holders
         thereof who are entitled to receive any dividend on, or any right to
         subscribe for, purchase or otherwise acquire any shares of stock of any
         class or any other securities or property, or to receive any other
         right, or

                  (b) any capital reorganization of the Company, any
         reclassification or recapitalization of the capital stock of the
         Company or any transfer of all or substantially all of the assets of
         the Company to or consolidation or merger of the Company with or into
         any other person, or

                  (c) any voluntary or involuntary dissolution, liquidation or
         winding-up of the Company,

then and in each such event the Company will mail or cause to be mailed to the
holder hereof, at least ten days prior to such record date, a notice specifying
(i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such
dividend, distribution or right; (ii) the date on which any such reorganization,
reclassification, recapitalization, transfer, consolidation, merger,
dissolution, liquidation or winding-up is to take place, and the time, if any is
to be fixed, as of which the holders of record of Common Stock (or other
securities) shall be entitled to exchange their shares of Common Stock (or other
securities) for securities or other property deliverable on such reorganization,
reclassification, recapitalization, transfer, consolidation, merger,
dissolution, liquidation or winding-up; and (iii) the amount and character of
any stock or other securities, or rights or options with respect thereto,
proposed to be issued or granted, the date of such proposed issue or grant and
the persons or class of persons to whom such proposed issue or grant is to be
offered or made.

                                       4
<PAGE>

Such notice shall also state that the action in question or the
record date is subject to the effectiveness of a registration statement under
the Securities Act of 1933, as amended, or a favorable vote of shareholders, if
either is required. Such notice shall be mailed at least ten days prior to the
date specified in such notice on which any such action is to be taken or the
record date, whichever is earlier.

14. NOTICES, ETC. All notices and other communications from the Company to the
registered holder of this Warrant shall be mailed by first class certified mail,
postage prepaid, at such address as may have been furnished to the Company in
writing by such holder or at the address shown for such holder on the register
of Warrants referred to in Section 6.

15. GOVERNING LAW. This Warrant shall be governed by and construed in accordance
with the laws of the State of Montana.

                                       5
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Warrant to be executed
by its duly authorized officers.

Dated:  July 29, 1999                  JORE CORPORATION,
                                       a Montana corporation

                                       By:________________________________
                                                Matt Jore, President

                                       6
<PAGE>

                                     ANNEX A

                          NOTICE OF EXERCISE/CONVERSION

         To:      JORE CORPORATION

         1. The undersigned Holder of the attached original, executed Warrant
hereby elects to exercise its purchase right under such Warrant with respect to
______________ Warrant Shares, as defined in the Warrant, of Jore Corporation, a
Montana corporation (the "Company").

         2. The undersigned Holder (check one):

                   -     elects to pay the aggregate purchase price for such
                         Warrant Shares (i) by lawful money of the United
                         States or the enclosed certified or official bank
                         check payable in United States dollars to the order
                         of the Company in the amount of $___________, or
                         (ii) by wire transfer of United States funds to the
                         account of the Company in the amount of
                         $____________, which transfer has been made before
                         or simultaneously with the delivery of this Form of
                         Exercise/Conversion pursuant to the instructions of
                         the Company;

                         or

                   -     elects to receive the number of Warrant Shares as
                         calculated in accordance with Section 2 of the
                         Warrant.

                                       7
<PAGE>

         3. Please issue a stock certificate or certificates representing the
appropriate number of shares of Common Stock in the name of the undersigned or
in such other names as is specified below:

                           Name:    _________________________

                           Address:    ____________________________________

                                       ____________________________________

    Dated:_____________________             ___________________________________
                                            (Signature must conform to name of
                                            Holder as specified on the face of
                                            the Warrant)

                                            ___________________________________

                                            ___________________________________
                                                      (Address)

                                      8
<PAGE>

                                     ANNEX B

                                 ASSIGNMENT FORM

         (To assign the foregoing Warrant, execute this form and supply required
information.)

         FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to

         _______________________________________________________
                  (Please Print)

         whose address is

         _______________________________________________________
                  (Please Print)

                                    Dated: ______________________

                                        Holder's Signature: ___________________

                                        Holder's Address: _____________________

                                        _______________________________________

         Guaranteed Signature:      __________________________________

         NOTE: The signature to this Assignment Form must correspond with the
name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatever, and must be guaranteed by a bank or trust company.
Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing
Warrant.

                                       9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]